Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2015

01-01-2015 | Epidemiology

Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses’ Health Studies

Authors: Megan S. Rice, Shelley S. Tworoger, Kimberly A. Bertrand, Susan E. Hankinson, Bernard A. Rosner, Yvonne B. Feeney, Charles V. Clevenger, Rulla M. Tamimi

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Abstract

Higher circulating prolactin levels have been associated with higher percent mammographic density among postmenopausal women in some, but not all studies. However, few studies have examined associations with dense area and non-dense breast area breast or considered associations with prolactin Nb2 lymphoma cell bioassay levels. We conducted a cross-sectional study among 1,124 premenopausal and 890 postmenopausal women who were controls in breast cancer case–control studies nested in the Nurses’ Health Study (NHS) and NHSII. Participants provided blood samples in 1989–1990 (NHS) or 1996–1999 (NHSII) and mammograms were obtained from around the time of blood draw. Multivariable linear models were used to assess the associations between prolactin levels (measured by immunoassay or bioassay) with percent density, dense area, and non-dense area. Among 1,124 premenopausal women, percent density, dense area, and non-dense area were not associated with prolactin immunoassay levels in multivariable models (p trends = 0.10, 0.18, and 0.69, respectively). Among 890 postmenopausal women, those with prolactin immunoassay levels in the highest versus lowest quartile had modestly, though significantly, higher percent density (difference = 3.01 percentage points, 95 % CI 0.22, 5.80) as well as lower non-dense area (p trend = 0.02). Among women with both immunoassay and bioassay levels, there were no consistent differences in the associations with percent density between bioassay and immunoassay levels. Postmenopausal women with prolactin immunoassay levels in the highest quartile had significantly higher percent density as well as lower non-dense area compared to those in the lowest quartile. Future studies should examine the underlying biologic mechanisms, particularly for non-dense area.
Literature
1.
go back to reference Byrne C et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87(21):1622–1629PubMedCrossRef Byrne C et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87(21):1622–1629PubMedCrossRef
2.
go back to reference Boyd NF et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675PubMedCrossRef Boyd NF et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675PubMedCrossRef
3.
go back to reference Tworoger SS, Hankinson SE (2008) Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 13(1):41–53PubMedCrossRef Tworoger SS, Hankinson SE (2008) Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 13(1):41–53PubMedCrossRef
5.
go back to reference Greendale GA et al (2007) Serum prolactin levels are positively associated with mammographic density in postmenopausal women. Breast Cancer Res Treat 105(3):337–346PubMedCrossRef Greendale GA et al (2007) Serum prolactin levels are positively associated with mammographic density in postmenopausal women. Breast Cancer Res Treat 105(3):337–346PubMedCrossRef
6.
go back to reference Bremnes Y et al (2007) Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 121(11):2506–2511PubMedCrossRef Bremnes Y et al (2007) Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 121(11):2506–2511PubMedCrossRef
7.
go back to reference Maskarinec G et al (2007) IGF-I and mammographic density in four geographic locations: a pooled analysis. Int J Cancer 121(8):1786–1792PubMedCrossRef Maskarinec G et al (2007) IGF-I and mammographic density in four geographic locations: a pooled analysis. Int J Cancer 121(8):1786–1792PubMedCrossRef
8.
go back to reference Tamimi RM et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev. 14(11 Pt 1):2641–2647CrossRef Tamimi RM et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev. 14(11 Pt 1):2641–2647CrossRef
9.
go back to reference Walker K et al (2009) Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res 69(16):6490–6499PubMedCrossRef Walker K et al (2009) Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res 69(16):6490–6499PubMedCrossRef
10.
go back to reference McCormack VA et al (2009) Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res 11(3):R38PubMedCentralPubMedCrossRef McCormack VA et al (2009) Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast Cancer Res 11(3):R38PubMedCentralPubMedCrossRef
13.
go back to reference Hoffmann T, Penel C, Ronin C (1993) Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J Endocrinol Invest 16(10):807–816PubMedCrossRef Hoffmann T, Penel C, Ronin C (1993) Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J Endocrinol Invest 16(10):807–816PubMedCrossRef
14.
go back to reference Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16(3):354–369PubMedCrossRef Sinha YN (1995) Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16(3):354–369PubMedCrossRef
15.
go back to reference Gout PW, Beer CT, Noble RL (1980) Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 40(7):2433–2436PubMed Gout PW, Beer CT, Noble RL (1980) Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 40(7):2433–2436PubMed
16.
go back to reference Tworoger, S.S., et al., (2014) Bioactive prolactin levels and risk of breast cancer: a nested case–control study. Cancer Epidemiol Biomark Prev Tworoger, S.S., et al., (2014) Bioactive prolactin levels and risk of breast cancer: a nested case–control study. Cancer Epidemiol Biomark Prev
17.
go back to reference Schernhammer ES et al (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomark Prev 14(3):699–704CrossRef Schernhammer ES et al (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomark Prev 14(3):699–704CrossRef
18.
go back to reference Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66(4):2476–2482PubMedCrossRef Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66(4):2476–2482PubMedCrossRef
19.
go back to reference Schernhammer ES, Hankinson SE (2009) Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomark Prev 18(1):74–79CrossRef Schernhammer ES, Hankinson SE (2009) Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomark Prev 18(1):74–79CrossRef
20.
go back to reference Hankinson SE et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396PubMedCrossRef Hankinson SE et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396PubMedCrossRef
21.
go back to reference Schernhammer ES et al (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13(2):583–592PubMedCrossRef Schernhammer ES et al (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13(2):583–592PubMedCrossRef
22.
go back to reference Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165–172CrossRef Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165–172CrossRef
23.
go back to reference Clevenger CV et al (1995) Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 146(3):695–705PubMedCentralPubMed Clevenger CV et al (1995) Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 146(3):695–705PubMedCentralPubMed
24.
go back to reference Rosner B et al (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167(6):653–666PubMedCrossRef Rosner B et al (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167(6):653–666PubMedCrossRef
25.
go back to reference Tamimi RM et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev 14(11):2641–2647CrossRef Tamimi RM et al (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev 14(11):2641–2647CrossRef
26.
go back to reference Emerman JT et al (1985) Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17(8):421–424PubMedCrossRef Emerman JT et al (1985) Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17(8):421–424PubMedCrossRef
27.
go back to reference Maddox PR, Jones DL, Mansel RE (1992) Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. Br J Cancer 65(3):456–460PubMedCentralPubMedCrossRef Maddox PR, Jones DL, Mansel RE (1992) Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. Br J Cancer 65(3):456–460PubMedCentralPubMedCrossRef
28.
go back to reference Missmer SA et al (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomark Prev 15(5):972–978CrossRef Missmer SA et al (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomark Prev 15(5):972–978CrossRef
29.
go back to reference Hankinson SE et al (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomark Prev 4(6):649–654 Hankinson SE et al (1995) Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomark Prev 4(6):649–654
Metadata
Title
Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses’ Health Studies
Authors
Megan S. Rice
Shelley S. Tworoger
Kimberly A. Bertrand
Susan E. Hankinson
Bernard A. Rosner
Yvonne B. Feeney
Charles V. Clevenger
Rulla M. Tamimi
Publication date
01-01-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3232-z

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine